10355-6 |
Observation |
Prid |
Bone mar |
Pt |
Nom |
Wright Giemsa stain |
|
ACTIVE |
Microscopic observation [Identifier] in Bone marrow by Wright Giemsa stain |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
10355-6 |
|
Wright Giemsa stain |
|
|
Both |
|
|
|
0 |
Wright Gie Stn Mar |
|
|
|
|
|
BM; BON; Bone marrow; Gie Stn; GMS; ID; Identity or presence; Infectious Disease; InfectiousDisease; MAR; Marrow (bone); Microbiology; minimal angle of resolution; Minimum angle of resolution; Nominal; Point in time; Random; St; Stains; Stn; UniversalLabOrders; Wright Gie Stn; Wrights |
2.78 |
1.0i |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Updated to seperate the component from the method; |
0 |
103550-0 |
Evaluation note |
Find |
Outpatient |
Pt |
Doc |
Physical therapy |
|
ACTIVE |
Physical therapy Outpatient Evaluation note |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
103550-0 |
|
Physical therapy |
|
|
|
|
|
|
0 |
PT OP Eval note |
|
|
|
N |
|
Assessment; DOC.ONT; Document; Encounter; Eval; Eval note; Evaluation and management; Evaluation and management note; Finding; Findings; H&P; History and physical; notes; OP; Point in time; PT; Random; Visit note |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
103551-8 |
Note |
Find |
Outpatient |
Pt |
Doc |
Brain injury |
|
ACTIVE |
Brain injury Outpatient Note |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
103551-8 |
|
Brain injury |
|
|
|
|
|
|
0 |
Brain injury OP Note |
|
|
|
N |
|
DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; notes; OP; Point in time; Random; Ulcer; Visit note |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
103552-6 |
Annual evaluation note |
Find |
{Setting} |
Pt |
Doc |
Psychology |
|
ACTIVE |
Psychology Annual evaluation note |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
103552-6 |
|
Psychology |
|
|
|
|
|
|
0 |
Psych Annual eval note |
|
|
|
N |
|
Annual eval note; Assessment; DOC.ONT; Document; Encounter; Eval; Eval note; Evaluation and management; Evaluation and management note; Finding; Findings; H&P; History and physical; notes; Point in time; Random; Visit note |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
103553-4 |
Summary note |
Find |
{Setting} |
Pt |
Doc |
Psychology |
|
ACTIVE |
Psychology Summary note |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
103553-4 |
|
Psychology |
|
|
|
|
|
|
0 |
Psych Summary note |
|
|
|
N |
|
DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; notes; Point in time; Random; Visit note |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
103554-2 |
Progress note |
Find |
{Setting} |
Pt |
Doc |
Surgical oncology |
|
ACTIVE |
Surgical oncology Progress note |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
103554-2 |
|
Surgical oncology |
|
|
|
|
|
|
0 |
Surg Onc Prog note |
|
|
|
N |
|
Cancer; DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; General surgical oncology; notes; Point in time; Prog note; Random; subsequent evaluation; subsequent visit evaluation; Surg; Surg Onc; Visit note |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
103555-9 |
Escherichia coli O157:H7 DNA |
PrThr |
Wound |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Escherichia coli O157:H7 DNA [Presence] in Wound by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
103555-9 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
E coli O157H7 DNA Wnd Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; E coli; E coli O157; E coli O157H7; Enterohemorrhagic E. coli; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; o002; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; Wnd |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
103556-7 |
PLA2G7 & PLAC8 gene expression level |
Score |
Bld |
Pt |
Qn |
Molgen |
|
ACTIVE |
PLA2G7 and PLAC8 gene expression level [Score] in Blood by Molecular genetics method |
|
ADD |
DefinitionDescription |
|
|
ratio |
|
|
|
|
|
|
MOLPATH |
|
103556-7 |
|
Molgen |
|
|
Both |
|
|
|
0 |
PLA2G7 & PLAC8 gene exp Bld |
|
|
|
N |
|
Blood; Levels; Levl; LV; LVL; Molecular genetics; Molecular pathology; MOLPATH; PCR; PLA2G7& PLAC8 gene exp; Point in time; QNT; Quan; Quant; Quantitative; Random; Scale; WB; Whole blood |
2.77 |
2.77 |
|
|
|
|
|
|
|
{ratio} |
|
|
|
0 |
103557-5 |
SARS coronavirus 2 Mpro gene mutation detected |
Prid |
XXX |
Pt |
Nom |
Molgen |
|
ACTIVE |
SARS-CoV-2 (COVID-19) Mpro gene mutation detected [Identifier] in Specimen by Molecular genetics method Nominal |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
103557-5 |
|
Molgen |
|
|
Both |
|
|
|
0 |
SARS-CoV-2 Mpro gene mut Spec |
|
|
|
N |
|
2019 Novel Coronavirus; 2019-nCoV; Corona virus; COVID19; COVID-19; Identity or presence; II; Misc; Miscellaneous; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mutations; Nominal; Other; PCR; Point in time; Random; SARS Coronavirus 1; SARS-CoV; SARS-CoV-1; SARS-CoV-2; SARS-CoV-2 Mpro gene mut; Severe Acute Respiratory Syndrome; Spec; To be specified in another part of the message; Unspecified; Viral Pneumonias; Wuhan coronavirus |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
103558-3 |
NR4A3 gene rearrangements |
Find |
Bld/Tiss |
Pt |
Doc |
FISH |
|
ACTIVE |
NR4A3 gene rearrangements in Blood or Tissue by FISH |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.REARRANGE |
|
103558-3 |
|
FISH |
|
|
Both |
|
|
|
0 |
NR4A3 gene Rear Bld/T FISH |
|
|
|
N |
|
Blood; CHN; CSMF; Document; Finding; Findings; Fluorescent in situ hybridization; MINOR; Molecular pathology; MOLPATH; MOLPATH.REARRANGEMENTS; NOR1; NR4A3 (9q22.33-q31.1) gene; Nuclear receptor subfamily 4, group A, member 3; Point in time; Random; Rearr; Rearrangement; TEC; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
103559-1 |
Rhinovirus RNA |
PrThr |
Nph |
Pt |
Ord |
Non-probe.amp.tar |
|
ACTIVE |
Rhinovirus RNA [Presence] in Nasopharynx by NAA with non-probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
103559-1 |
|
Non-probe.amp.tar |
|
|
Both |
|
|
|
0 |
Rhinovirus RNA Nph Ql NAA+non-probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; HRV; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+non-probe; NAA+probe; NAAT; NASBA; Nasopharynx; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Rhino virus; RHV; Ribonucleic acid; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
10356-4 |
Microscopic observation |
Prid |
Stool |
Pt |
Nom |
Trichrome stain |
|
DEPRECATED |
Deprecated Microscopic observation [Identifier] in Stool by Trichrome stain |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
10356-4 |
|
Trichrome stain |
|
|
|
|
|
|
0 |
Deprecated Tri Stn Stl |
|
|
|
|
|
Bowel movement; Faecal; Faeces; Fecal; Feces; Gastro; Gastroenterology; GI; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; Point in time; Random; St; Stains; Stl; Stn; Stool = Fecal; Tri Stn |
2.36 |
1.0i |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
103560-9 |
Aldosterone/Renin |
Ratio |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Aldosterone/Renin [Ratio] in Serum or Plasma |
|
ADD |
DefinitionDescription |
|
|
{ratio} |
|
|
|
|
|
|
CHEM |
|
103560-9 |
|
|
|
|
Both |
|
|
|
0 |
Aldost/Renin SerPl-Rto |
|
|
|
N |
|
Angiotensin forming enzyme; Angiotensinogenase; Chemistry; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Ratios; Rto; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.77 |
2.77 |
|
|
|
|
|
|
|
{ratio} |
|
|
|
0 |
103562-5 |
AB-Fubinaca metabolite 3 |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
AB-Fubinaca metabolite 3 [Mass/volume] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
103562-5 |
|
Confirm |
|
|
Both |
|
|
|
0 |
AB-Fubinaca met 3 Ur Cfm-mCnc |
|
|
|
N |
|
Ab-fubinaca acid metabolite; AB-Fubinaca met 3; Amb-fubinaca acid metabolite; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; III; LC/MS/MS; Level; Mass concentration; Metab; Metabolites; Metb; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.77 |
2.77 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
103563-3 |
Minimum Data Set (MDS) - version 3.0 - Resident Assessment Instrument (RAI) version 1.19.1 |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
Minimum Data Set (MDS) - version 3.0 - Resident Assessment Instrument (RAI) version 1.19.1 [CMS Assessment] |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
103563-3 |
|
CMS Assessment |
|
|
Order |
|
|
|
0 |
|
|
|
|
N |
|
Centers for Medicare and Medicaid Assessment; MDS; MDS - version 3.0 - RAI version 1.19.1; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.79 |
2.78 |
|
Convenience group |
|
|
|
|
|
|
|
|
|
0 |
103564-1 |
MDS v3.0 - RAI v1.19.1 - Nursing home comprehensive (NC) item set |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
MDS v3.0 - RAI v1.19.1 - Nursing home comprehensive (NC) item set during assessment period [CMS Assessment] |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
103564-1 |
|
CMS Assessment |
|
|
Order |
|
|
|
0 |
|
|
|
|
N |
|
Centers for Medicare and Medicaid Assessment; MDS v3.0 - RAI v1.19.1 - NC; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.79 |
2.78 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
103565-8 |
HIV 1 group O RNA+HIV 1 group M RNA+HIV 2 RNA+Hepatitis C virus RNA+Hepatitis B virus DNA+Hepatitis E virus RNA |
PrThr |
Ser/Plas/Bld^Donor |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
HIV 1 group O RNA+HIV 1 group M RNA+HIV 2 RNA+Hep C RNA+Hep B DNA+Hep E RNA [Presence] in Serum, Plasma or Blood from Donor by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
103565-8 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HIV1,2+HCV+HEV RNA+HBV DNA S/P/B Dr Napb |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; AIDS; Amplif; Amplification; Amplified; Blood; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Donr; HBV; HCV; Hep; Hep B; Hep C; Hep E; Hepatis; Hepatit; HepB; HEV; HEV RNA; HIV type 1; HIV type 2; HIV type I; HIV type II; HIV1; HIV1,2+HCV+HBV+HEV; HIV1+HIV2+HCV+HBV; Human immunodeficiency virus; i; II; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Pl; PlasBld; Plasma; Plsm; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; Screen; SDA; SerP; SerPl; SerPlas; SerPlBld; Serum; Serum or plasma; Serum, plasma or whole blood; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
103566-6 |
Metagenomic DNA and RNA Sequencing |
Prid |
CSF |
Pt |
Nom |
Sequencing |
|
ACTIVE |
Metagenomic DNA and RNA Sequencing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
103566-6 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
MSCSF DNA & RNA |
|
|
|
N |
|
Cerebral spinal fluid; Cerebrospinal Fl; Deoxyribonucleic acid; high-throughput sequencing; HTS; Identity or presence; Metagenomic DNA & RNA; Molecular pathology; MOLPATH; Next generation sequencing; NGS; Nominal; Point in time; Random; Ribonucleic acid; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
103567-4 |
Previous cancer therapy |
Prid |
^Patient |
Pt |
Nar |
|
|
ACTIVE |
Previous cancer therapy (narrative) |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ATTACH.CLINRPT |
|
103567-4 |
|
|
|
|
Observation |
|
|
|
0 |
Path report IG |
|
|
|
N |
|
ATTACH; ATTACH.CLINRPT; Identity or presence; Narrative; Point in time; Prev; Prev CA Tx; Random; Report |
2.78 |
2.77 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: PROPERTY: This code should not be a doc_ontology and Prid is the appropriate value to attachments. ; |
0 |
103568-2 |
COVID-19 Vaccine |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
MDS v3.0 - RAI v1.19.1 - COVID-19 Vaccine [CMS Assessment] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
103568-2 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
N |
|
2019 Novel Coronavirus; 2019-nCoV; Centers for Medicare and Medicaid Assessment; Coronavirus disease 2019; COVID19; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; SARS Coronavirus; SARS-CoV-2; SARS-Related Coronavirus; Survey |
2.77 |
2.77 |
|
Organizer |
|
|
|
|
|
|
|
|
|
0 |
103569-0 |
Is the resident's COVID-19 vaccination up to date? |
Find |
^Patient |
RptPeriod |
Ord |
CMS Assessment |
|
ACTIVE |
MDS v3.0 - RAI v1.19.1 - Is the resident's COVID-19 vaccination up to date? [CMS Assessment] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.CMS |
|
103569-0 |
|
CMS Assessment |
|
|
Observation |
|
|
|
0 |
|
|
|
|
N |
|
2019 Novel Coronavirus; 2019-nCoV; Centers for Medicare and Medicaid Assessment; Coronavirus disease 2019; COVID19; Finding; Findings; Immunizations; Ordinal; Ql; Qual; Qualitative; Report period; S prime; SARS Coronavirus; SARS-CoV-2; SARS-Related Coronavirus; Screen; Survey; Vaccine |
2.78 |
2.78 |
|
|
|
|
|
|
|
|
|
|
|
0 |
10357-2 |
Observation |
Prid |
Wound |
Pt |
Nom |
Gram stain |
|
ACTIVE |
Microscopic observation [Identifier] in Wound by Gram stain |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
10357-2 |
|
Gram stain |
|
|
Both |
|
|
|
0 |
Gram Stn Wnd |
|
|
|
|
|
Gram Stn; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; Point in time; Random; St; Stains; Stn; Wnd |
2.78 |
1.0i |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Updated to seperate the component from the method; |
0 |
103570-8 |
AAV serotype rh74 Ab |
PrThr |
Ser/Plas |
Pt |
Ord |
IA |
|
ACTIVE |
AAV serotype rh74 Ab [Presence] in Serum or Plasma by Immunoassay |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
103570-8 |
|
IA |
|
|
Both |
|
|
|
0 |
AAVrh74 Ab SerPl Ql IA |
|
|
|
N |
|
AAVrh74; ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; MEIA; Microbiology; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; SUDS |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
103571-6 |
Study observation^W fluorescein IV |
Find |
Ocular fundus |
Pt |
Nom |
Angiography |
|
ACTIVE |
Study observation Ocular fundus Angiography W fluorescein IV |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
EYE.ANGIO |
|
103571-6 |
|
Angiography |
|
|
Both |
|
|
|
0 |
Stdy obs Ocular fund Angio W fluoresc IV |
|
|
|
N |
|
Angio; EYE; EYE.ANGIO; Finding; Findings; Nominal; Point in time; Random; Study report; W fluoresc IV |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
103572-4 |
Cosmetic product listing |
- |
^FDA package insert |
- |
Nar |
|
|
ACTIVE |
FDA package insert Cosmetic product listing |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOCUMENT.REGULATORY |
|
103572-4 |
|
|
|
|
Both |
|
|
|
0 |
FDA insert Cosmetic product listing |
|
|
|
N |
|
DOCUMENT.REGULATORY; FDA insert; Narrative; Report; SPL; Structured Product Labelling |
2.78 |
2.77 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: PROPERTY: Removed property not needed for FDA concepts; TIME_ASPCT: Removed Time not needed for FDA concepts; |
0 |